There’s a new biotech on the scene after MoonLake Immunotherapeutics launched on a mission to develop sonelokimab, a potential inflammatory diseases drug in-licensed from Germany’s Merck KGaA. The ...
Nepal: Pyoderma gangrenosum (PG) can occur without associated systemic disease and may resemble infectious or vascular ulcers ...
A mum was unable to see her baby for three months after a flesh-eating bug infected her c-section scar - leaving her using a wheelchair for nine years. Kelly Simmons, 44, was rushed back into hospital ...
A mother was separated from her newborn for three months after a flesh-eating infection attacked her caesarean section scar - ultimately confining her to a wheelchair for nine years. Kelly Simmons, 44 ...
KELLY Simmons was left wheelchair-bound for nine years after a flesh-eating bug infected her C-section scar, as a result of doctors using unsterile tools. The 44-year-old was rushed back into hospital ...
Jena, Germany, March 30, 2026 (GLOBE NEWSWIRE)-- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced ...
Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original ...
Multiple myeloma rarely affects the skin, but it can cause plasmacytoma, ulcers, or bruising. Skin issues may occur when plasma cells build up, abnormal M protein accumulates, or medications irritate ...
MADISON, N.J.--(BUSINESS WIRE)--LEO Pharma A/S, a global leader in medical dermatology, today announced it will present 23 scientific posters at Maui Derm Hawaii 2026 (Jan. 25-29), showcasing a ...
Doctors should closely monitor patients with GPP for signs of PG, including a thorough assessment of painful ulcers of undetermined origin. A diagnosis of generalized pustular psoriasis (GPP) is ...
InflaRx N.V. (NASDAQ: IFRX) is reviving hopes for vilobelimab after new analyses showed signs of efficacy in a Phase 3 trial it had previously halted, setting up FDA talks and a potential partner-led ...
Although it looked to be lights out for InflaRx’s C5a antibody vilobelimab in the rare skin disorder pyoderma gangrenosum (PG) last year, the German drugmaker ended 2025 with a glimmer of hope for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results